3150 results for «248»
3150 results
Mastering techniques from basic to complex - Advanced TAVI
13 Feb 2026 – From PCR Tokyo Valves 2026
Explore advanced TAVI techniques focusing on challenging patient subsets such as those with small annuli, bicuspid valves, and valve-in-valve procedures. This session reviews valve selection and procedural optimization to enhance clinical outcomes in complex scenarios.
Design that delivers the future of TAVI
13 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses future-oriented TAVI valve design and procedural planning. It highlights supra-annular valve benefits, strategies for managing concomitant coronary artery disease, and redo-TAVI approaches to ensure long-term durability and optimal hemodynamics.
Mastering LAA closure: a step-by-step case experience
14 Feb 2026 – From PCR Tokyo Valves 2026
This session presents a step-by-step, case-based approach to mastering left atrial appendage (LAA) closure. It covers pre-procedural planning, device-specific strategies, complication prevention, and complex bailout techniques such as leak closure with coiling or dual-device implantation.
Patient-tailored treatment for bicuspid valve
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on patient-tailored treatment for bicuspid aortic valve stenosis, providing comprehensive insights into the evidence base for TAVI in this population. It discusses critical considerations for valve selection and sizing, and highlights anatomical features that may pose challenges for TAVI procedures. Case studies illustrate...
Mastering mitral TEER: guidelines, complex cases, and Asia Pacific insights
14 Feb 2026 – From PCR Tokyo Valves 2026
This session provides an in-depth analysis of mitral transcatheter edge-to-edge repair (TEER) in light of the 2025 ESC Valvular Heart Disease guidelines. It addresses optimal timing and treatment strategies for severe heart failure beyond established trials, and explores technical solutions for complex anatomies. Special attention is...
Mitral TEER masterclass
14 Feb 2026 – From PCR Tokyo Valves 2026
This Mitral TEER masterclass focuses on addressing unique anatomical challenges encountered in Asian populations. The session covers device strategies and techniques tailored for complex anatomies, offering practical tips to minimize complications and improve procedural outcomes through detailed case analyses including small hearts, commissural prolapse with calcification,...
Real world outcomes and strategies for optimal TEER across diverse DMR anatomies
14 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the real-world complexities of degenerative mitral regurgitation (DMR) and presents advanced strategies for transcatheter edge-to-edge repair (TEER) using the PASCAL device. Participants will explore the latest registry data, device selection criteria, and tactical approaches to manage diverse and challenging DMR anatomies, aiming...
All you need to know about redo TAVI
15 Feb 2026 – From PCR Tokyo Valves 2026
This comprehensive session addresses the complexities of redo Transcatheter Aortic Valve Implantation (TAVI). It covers the full spectrum from pre-procedural analysis—including coronary obstruction risk and valve sizing—to procedural strategies like leaflet modification and optimal positioning. Post-procedural management including antithrombotic therapy and patient-prosthesis mismatch are also examined,...
RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure
01 Sep 2024
Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.
The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...
Author
Insights from the Corevalve US Pivotal and SURTAVI trials
05 Apr 2022
Pierre Deharo and Giuseppe Di Gioia provide their take on this analysis of the 5 years incidence, outcomes and predictors of hemodynamic SVD in patients undergoing TAVI and surgery from the Corevalve US Pivotal and SURTAVI trials.
Author
Author
